Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
Article
Google Scholar
Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688.
Article
Google Scholar
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
Article
Google Scholar
Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851–62.
Article
CAS
Google Scholar
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439–57.
Article
CAS
Google Scholar
Kulkarni NM, Soloff EV, Tolat PP, Sangster GP, Fleming JB, Brook OR, et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology’s disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol (NY). 2020;45(3):716–28.
Article
Google Scholar
Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022;74(1):35–42.
Article
Google Scholar
Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220–30.
Article
CAS
Google Scholar
Soloff EV, Al-Hawary MM, Desser TS, Fishman EK, Minter RM, Zins M. Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2022;218(4):570–81.
Article
Google Scholar
Heinrich S, Lang H. Neoadjuvant therapy of pancreatic cancer: definitions and benefits. Int J Mol Sci. 2017;18(8):1622.
Article
Google Scholar
Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–23.
Article
Google Scholar
Townend P, de Reuver PR, Chua TC, Mittal A, Clark SJ, Pavlakis N, et al. Histopathological tumor viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. ANZ J Surg. 2018;88(3):E167–72.
Article
Google Scholar
Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.
Article
CAS
Google Scholar
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.
Article
CAS
Google Scholar
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–7.
Article
Google Scholar
Treadwell JR, Zafar HM, Mitchell MD, Tipton K, Teitelbaum U, Jue J. Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma: A meta-analysis. Pancreas. 2016;45(6):789–95.
Article
CAS
Google Scholar
White RR, Paulson EK, Freed KS, Keogan MT, Hurwitz HI, Lee C, et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg. 2001;5(6):626–33.
Article
CAS
Google Scholar
Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133(10):1539–51.
Article
Google Scholar
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307–10.
Article
CAS
Google Scholar
Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70(4):213–20.
Article
CAS
Google Scholar
Verbeke CS, Knapp J, Gladhaug IP. Tumor growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology. 2011;59(6):1111–21.
Article
Google Scholar
Wang H, Zhao Q. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. Ann Diagn Pathol. 2012;16(5):427.
Article
Google Scholar
Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(20):2324–8.
Article
CAS
Google Scholar
Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.
Article
Google Scholar
Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan pancreas society: a synopsis. Pancreas. 2020;49(3):326–35.
Article
Google Scholar
Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: a summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology. 2021;21(7):1326–41.
Article
Google Scholar
Ma C, Yang P, Li J, Bian Y, Wang L, Lu J. Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens. Abdom Radiol (NY). 2020;45(3):782–8.
Article
Google Scholar
Bian Y, Jiang H, Cao K, Mms XF, Li J, Ma C, et al. The relationship between microscopic tumor size and CT tumor size in pancreatic ductal adenocarcinoma. Clin Imaging. 2021;76:30–7.
Article
Google Scholar
Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2011;80(5):1383–90.
Article
Google Scholar
Hall WA, Mikell JL, Mittal P, Colbert L, Prabhu RS, Kooby DA, et al. Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2013;86(1):102–7.
Article
Google Scholar
Bian Y, Jiang H, Zheng J, Shao C, Lu J. Basic pancreatic lesions: radiologic-pathologic correlation. J Transl Int Med. 2022;10(1):18–27.
Article
Google Scholar